risk of malignant melanoma also increases in PUVA patients, especially among those who received at least 250 PUVA 8-Methoxypsoralen (8-MOP) plus UVA irradiation (PUVA treatments. These results raise the question of whether PUVA therapy) has been used for the treatment of psoriasis.
should be abandoned (Wolff, 1997) . PUVA therapy has been associated with an increased risk 8-MOP intercalates between DNA base pairs and, following of developing skin squamous cell carcinoma (SCC). In order UVA irradiation, undergoes photocycloaddition with pyrito determine the PUVA-induced p53 mutation spectrum, a midines in a sequence-dependent manner to generate monoyeast expression vector harbouring a human wild-type p53 adducts and interstrand crosslinks at 5Ј-TpA sites (Cimino cDNA was incubated with 8-MOP, and UVA irradiated et al., 1985; Sage and Moustacchi, 1987) . Monoadducts in vitro. PUVA-damaged and undamaged DNA was transinduced by a bifunctional psoralen like 8-MOP are derived by fected into a yeast strain containing the ADE2 gene reguphotoaddition between the 5,6 double bond of a pyrimidine lated by a p53-responsive promoter. An 8-MOP and a double bond in the furan-(4Ј,5Ј) or pyrone-(3,4) rings concentration-dependent decrease in survival and increase of the psoralen. At 5Ј-TpA sites a monoadduct can absorb a in mutant frequency were observed. At a fixed 8-MOP second UVA photon with the formation of an interstrand concentration, survival decreased and mutant frequency crosslink. Mutagenesis studies in rodent or human cell lines increased as UVA irradiation increased. Eleven mutant reveal that 8-MOP leaves a highly specific mutation signature clones contained 11 mutations: 10 were single base pair (T:A-targeted base pair substitutions at 5Ј-TpA sites) (Sage substitutions, the remaining one being a complex mutation . et al., 1993; Yang et al., 1994; Gunther et al., 1995 ; Laquerbe All eight T:A-targeted mutations were at 5Ј-TpA sites , et al., 1995) . hallmark mutations of PUVA mutagenesis. Through a
The p53 protein regulates expression of a number of genes rigorous statistical test, the PUVA-induced p53 mutation playing an important role in the control of cell cycle progression spectrum appears to differ significantly (P < 0.0002) from and apoptosis (Ko and Prives, 1996) . This main but not unique that observed in SCC in PUVA-treated patients. The present function requires selective recognition and binding to specific work demonstrates that a specific PUVA-induced muta-DNA sequences by the DNA-binding domain of the protein tional fingerprint could be obtained and recognized on and a functional oligomerization domain that mediates the human p53 cDNA. This result may suggest that PUVA therapy can be a risk factor for the development of SCC formation of active tetramers. Alterations in the p53 gene are in psoriasis patients through a mechanism not involving the most common genetic defects known to occur in human the induction of p53 mutations.
tumours (Greenblatt et al., 1994) . About 80% of such alterations are missense mutations, the most informative alterations in mutation spectrometry studies. Similarities have been observed Introduction between the features of p53 mutations observed in specific tumours and the mutagenic specificity (determined in different 8-Methoxypsoralen (8-MOP) plus UVA irradiation (PUVA genes) of aetiological agents known to be a risk factor for therapy) has been used for the treatment of psoriasis (Parrish such tumors. This evidence suggests a role for aflatoxin et al., 1974) . 8-MOP is ingested, and 2 h later the patient is B1, UV light and tobacco smoke in the development of exposed to long wavelength UV irradiation (UVA, λ ϭ 320-hepatocellular carcinomas (Bressac et al., 1991; Hsu et al., 400 nm) . Neither the drug nor the UVA irradiation is effective 1991), non-melanoma-skin cancers (NMSC) (Brash et al., alone. Given the penetration characteristics of UVA Ziegler et al., 1994) and lung carcinomas (Greenblatt absorption of photons is confined to the skin), PUVA therapy et al., 1994; Brennan et al., 1995) , respectively. A limitation is a form of targeted chemotherapy. Several studies have inherent in these studies is the failure to experimentally shown that PUVA is a mutagen and carcinogen (Bredberg and reproduce the observed p53 mutation spectra. Only recently Nachmansson, 1987; Sage et al., 1993; Yang et al., 1994;  has a yeast-based approach to select p53 mutants for the Gunther et al., 1995; Nataraj et al., 1996) and may have transactivation function become available (Inga et al., 1997a) . immunosuppressive effects (Kraemer et al., 1981; Moscicki Using this system we confirmed that carcinogens induce et al., 1982; Bredberg et al., 1983; Kripke et al., 1984;  different experimental p53 mutation fingerprints and we also Gasparro et al., 1997 Recently p53 mutations in tumours developed in PUVAof adenine, adenine auxotrophs were able to achieve only a few cell divisions treated mice (Nataraj et al., 1996) a random number generator to produce a large number of simulated spectra
Here we report the determination of a PUVA-induced based on the hypergeometric probability of the experimentally observed input mutation spectrum for human p53 cDNA using a yeast funcspectra. The degree to which the simulated spectra differ from the input tional assay. We also tested whether the molecular features of spectra is used to estimate the probability that the two input spectra were the p53 mutations observed in yeast support the notion of a derived from the same population. A P value Ͻ0.05 leads one to reject the null hypothesis and conclude that the input spectra are different. (10 kJ/m 2 ) had no effect on survival per se, while it slightly 20 mutant clones was also searched for by direct transformation were selected on plates lacking leucine, we reasoned that of these 20 clones were amplifiable. We concluded that in the majority of phenotypically mutant clones p53 cDNA was lost a All T:A-targeted mutations are at 5Ј-TpA.
along with most of the plasmid, except for the LEU marker, b -1C and a TC→AG tandem mutation.
which was probably chromosomally integrated. It is possible that the presence of PUVA-induced interstrand crosslinks -1C deletion). All T:A-targeted mutations were in 5Ј-TpA-3Ј strongly inhibited plasmid replication and concomitantly sequences (Table III) . favoured recombination events, causing the loss of p53 cDNA.
PCR fragments obtained from the 11 amplifiable samples Discussion tested by gap repair invariably gave 100% red colonies after gap repair and showed p53 mutations by DNA sequencing.
One of the tasks of molecular epidemiology is to help in identifying carcinogens that induce a specific cancer. Since Table II reports the complete list of the 11 mutations identified, with information on the type of mutation and the amino acid most carcinogens leave specific mutation fingerprints, the mutation spectrometry approach can be used in identifying change. All 10 single mutations were base pair substitutions, mainly (8/10, 80%) T:A-targeted (Table III) . The remaining factors involved in tumorigenesis (Harris, 1993). PUVA therapy is an effective treatment for severe psoriasis, mutation is a complex mutation (tandem mutation and a but was unfortunately shown to be mutagenic and carcinogenic Table IV . Molecular features of p53 mutations induced by 8-MOP ϩ UVA in experimental systems (Bredberg and Nachmansson, 1987;  in different systems Sage et al., 1993; Yang et al., 1994; Gunther et al., 1995; Nataraj et al., 1996) . PUVA therapy constitutes a risk factor treated with it (Stern et al., 1984 (Stern et al., , 1988 (Stern et al., , 1994 (Stern et al., , 1997a Bruynzeel Base pair substitution 15 10 24
et Lindelöf et al., 1991; Lever and Farr, 1994; Maier Frameshift 2 et al., 1996) . It was estimated that high dose PUVA (Ͼ300 SCC, with lower risks of 20-and 10-fold for medium and low
Single and non-tandem base pair substitutions dose exposures, respectively (Stern et al., 1994) . Surprisingly,
p53 mutations in skin tumours which developed in PUVA-CG→T A 1 1 6 treated human patients (Nataraj et al., 1997; Wang et al., 1997) CG→A T 2 1 5 or in mice (Nataraj et al., 1996) were only partially consistent
with the known mutational specificity for PUVA. In the present UVA determined in different experimental systems (Cimino a Data from Nataraj et al. (1996 Nataraj et al. ( ). et al., 1985 Sage and Moustacchi, 1987; Sage et al., 1993; Data from this work. Yang et al., 1994; Gunther et al., 1995; Laquerbe et al., 1995) :
c Data from Nataraj et al. (1997) and Wang et al. (1997) .
mutations were mainly (8/10, 80%) T:A-targeted, located at
5Ј-TpA sites. The genotoxicity of 8-MOP has been attributed to its ability to covalently bind to DNA upon UVA irradiation. 8-MOP intercalates between DNA base pairs and, following and, when applicable, through the Cariello program, which UVA irradiation, undergoes photocycloaddition with pyrimidprovides a precise measure of the relatedness of two spectra ines (mainly thymine) in a sequence-dependent manner (Cariello et al., 1994) . (Cimino et al., 1985; Sage and Moustacchi, 1987) to generate When classes of mutations were considered (Table IV) , only monoadducts and/or interstrand crosslinks. The 5Ј-TpA site is the yeast system shows 100% T:A-targeted mutations at 5-the preferred target for the formation of monoadducts and the TpA sequences, the hallmark of 8-MOP ϩ UVA mutagenesis, exclusive one for interstrand crosslinks (Sage and Moustacchi, an incidence significantly higher than in mice (P Ͻ 0.05, 1987). Our results also confirmed the strand bias observed in Fisher's exact test) and in human tumours (P Ͻ 0.0001, previous studies (Sage et al., 1993; Yang et al., 1994; Gunther Fisher's exact test). Consistently, the incidence of T: A-targeted et al., 1995; Laquerbe et al., 1995) . The strand bias is consistent mutations at TpA sites is non-significantly different between with the observation that in mammalian cells psoralen mouse and yeast. interstrand crosslinks and/or monoadducts are preferentially No p53 mutations induced by 8-MOP ϩ UVA in yeast were removed from the transcribed strand of actively transcribed found in skin tumours induced in PUVA-treated patients genes compared with the genome overall (Vos and Hanawalt, (Nataraj et al., 1997; Wang et al., 1997) . Overall, statistical 1987; Islas et al., 1991) . In our system, where transcription of comparison using the Cariello program considering both type the target gene (p53) is necessary for the mutation assay, we and site of mutations revealed that the two p53 mutation observed that 75% (6/8) of 5Ј-TpA-targeted mutations can be spectra are clearly different (P Ͻ 0.0002) (Figure 1 ). We could interpreted as derived from a lesion present on the nonnot perform a Cariello analysis between the yeast and the mice transcribed strand. spectra since the two genes have different nucleotide sequences. The PUVA fingerprint in yeast is significantly different from
The difference between the yeast and the human p53 spectra those induced in the same experimental system by UV light is significant and interesting, but some caution in the conclu-(P Ͻ 0.05) (Inga et al., 1998) and by chloroethyl cyclohexyl sions has to be exercised. Certainly the yeast p53 functional nitrosourea (P Ͻ 0.02) (Inga et al., 1997a) when comparisons assay has some interesting features (e.g. it is based on a pivotal are performed by considering both mutation type and location function of p53, whose gene is frequently mutated in tumours). of the alteration in the p53 gene through a rigorous statistical However, it also has some drawbacks: (i) the damaging test that provides a precise measure of the relatedness of two treatment is done in vitro and the influence, for example, of spectra (Cariello et al., 1994) . chromatin structure is not taken into account; (ii) the target is 8-MOP ϩ UVA-induced p53 mutation spectra in yeast and cDNA and not the entire gene; (iii) p53 is basically a in skin cancer developed in PUVA-treated human patients transcription factor but it also exerts transcription-independent are different functions. Futhermore, when one compares p53 mutations obtained in yeast with those observed in tumours another level The mutation spectrum induced by PUVA in the p53 cDNA in yeast (this work) was compared with that obtained in mice of complexity is added. Why is the PUVA fingerprint not found in SCC induced in (Nataraj et al., 1996) and with that obtained in SCC induced in PUVA-treated patients (Nataraj et al., 1997; Wang et al., PUVA-treated patients? Gasparro et al. (1998) hypothesized that a bias against the detection of mutations at T:A sites could 1997). Comparisons were performed by class of mutations
In conclusion, we have shown that the generation of a mutation fingerprint for the human p53 cDNA sequence by the yeast functional assay can represent a useful tool in the field of cancer molecular epidemiology (Vogelstein and Kinzler, 1992; Harris, 1993) . In fact, a comparison of the experimentally obtained p53 mutation fingerprints with spectra obtained in human tumours can take into account all the informational richness contained in a p53 mutation spectrum, i.e. simultaneously consider both type and position of all mutations. The present approach can be used to pinpoint the aetiological agent of specific tumours (e.g. UV or NMSC; see Inga et al., 1998) or can contribute in elucidating the molecular mechanism by which an agent is carcinogenic. 
